Pharmaceutical Companies Announce Trial Results, and Achieve New Contracts, Regulatory Approvals, and Positive Opinion -

 Pharmaceutical Companies Announce Trial Results, and Achieve New Contracts,
  Regulatory Approvals, and Positive Opinion - Research Report on Eli Lilly,
                  Pfizer, Novartis, Sanofi, and AstraZeneca

PR Newswire

NEW YORK, October 1, 2013

NEW YORK, October 1, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Eli
Lilly and Company (NYSE: LLY), Pfizer Inc. (NYSE: PFE), Novartis AG (NYSE:
NVS), Sanofi (NYSE: SNY), and AstraZeneca PLC (NYSE: AZN). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

Eli Lilly and Company Research Report

On September 26, 2013, Eli Lilly and Company (Lilly) announced top-line
results from two global Phase III studies of ramucirumab (IMC-1121B).
According to Lilly, the top-line results were from the Phase III studies for
advanced gastric cancer and metastatic breast cancer. Lilly reported that the
RAINBOW trial for advanced gastric cancer achieved its primary endpoint of
improved overall survival and a secondary endpoint of improved
progression-free survival. The Company also reported that the ROSE Phase III
study of ramucirumab in women with locally recurrent or metastatic breast
cancer did not meet its primary endpoint of progression-free survival.
Commenting on the results, Richard Gaynor, M.D., Vice President, Product
Development and Medical Affairs for Lilly Oncology, stated, "We are
disappointed that this breast cancer trial did not meet its primary endpoint.
However, now with two positive gastric cancer trials, Lilly remains confident
in the overall ramucirumab development program. We are looking forward to
additional Phase III results for ramucirumab in colorectal, hepatocellular and
lung cancer, expected in 2014." The Full Research Report on Eli Lilly and
Company - including full detailed breakdown, analyst ratings and price targets
- is available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-09-26/LLY]

--

Pfizer Inc. Research Report

On September 25, 2013, Pfizer Inc. (Pfizer) reported that its wholly owned
subsidiary Meridian Medical Technologies, Inc. (Meridian) was awarded a
five-year contract by the Biomedical Advanced Research & Development Authority
(BARDA) of the US Department of Health and Human Services' Office of the
Assistant Secretary for Preparedness and Response (ASPR). According to the
Company, the $60 million contract is associated with a program authorized
under Project Bioshield, and its objective is to develop midazolam
auto-injectors as a replacement for the diazepam auto-injectors currently in
the Strategic National Stockpile (SNS) as a medical countermeasure against
nerve-agent exposure. The Full Research Report on Pfizer Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.InvestorsReports.com/report/2013-09-26/PFE]

--

Novartis AG Research Report

On September 23, 2013, Novartis AG (Novartis) announced that it has received
an approval from the European Commission for once-daily Ultibro® Breezhaler®
(indacaterol 85 mcg / glycopyrronium 43 mcg) as a maintenance bronchodilator
treatment to relieve symptoms in adult patients with chronic obstructive
pulmonary disease (COPD). Moreover, Novartis reported that the Japanese
Ministry of Health, Labour and Welfare (MHLW) approved once-daily Ultibro®
Inhalation Capsules (glycopyrronium 50 mcg / indacaterol 110 mcg), delivered
through the Breezhaler® device, for relief of various symptoms due to airway
obstruction in chronic obstructive pulmonary disease (COPD). David Epstein,
Division Head, Novartis Pharmaceuticals, commented, "We are very pleased that
the European Commission and Japan approved QVA149, nearly simultaneously, for
COPD patients. This rapid approval in Japan reflects our build-up of clinical
trial and regulatory capabilities in Japan." Epstein added, "Many COPD
patients will now have a better treatment option, including first-line therapy
with the launch of Ultibro Breezhaler in Europe." The Full Research Report on
Novartis AG - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-09-26/NVS]

--

Sanofi Research Report

On September 24, 2013, Sanofi announced new GetGoal-L sub-analysis results
showing that reductions in HbA[1c] with Lyxumia® (lixisenatide), when added to
basal insulin, were greatest in patients with type 2 diabetes who had
well-controlled baseline fasting plasma glucose (FPG). Sanofi reported that
the findings are in line with the efficacy profile of Lyxumia, which shows a
clinical and statistically significant reduction in HbA[1c] across different
patient populations. Commenting on the results, Professor Josep Vidal,
Endocrinology and Nutrition, University of Barcelona, said, "The study showed
that Lyxumia is an effective post-prandial glucose lowering option that
improves HbA[1c] levels when added to basal insulin." Vidal continued, "We
analyzed data from patients who were not at their target HbA[1c] level,
despite controlled fasting plasma glucose, and we found that a treatment
regimen that targets postprandial glucose, as well as fasting plasma glucose,
could be an effective choice for these patients." The Full Research Report on
Sanofi - including full detailed breakdown, analyst ratings and price targets
- is available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-09-26/SNY]

--

AstraZeneca PLC Research Report

On September 20, 2013, AstraZeneca PLC (AstraZeneca) announced that the
Committee for Medicinal Products for Human Use (CHMP) of the European
Medicines Agency (EMA) has issued a positive opinion on Fluenz Tetra.
According to AstraZeneca, Fluenz Tetra is a nasally administered four-strain
live attenuated influenza vaccine, for the prevention of seasonal influenza in
eligible children and adolescents 24 months to 17 years of age. Further,
AstraZenca reported that the positive opinion was reached after a review of
data from a pivotal paediatric study, which indicated that the safety and
immunogenicity profile of Fluenz Tetra was comparable to the three-strain
(trivalent) vaccine, Fluenz. The Full Research Report on AstraZeneca PLC -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-09-26/AZN]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Investors' Reports

Contact: Kristi Saunders : +1-315-982-6420 (North America)